Although nicotine’s signaling through its receptors is well-defined, how cAMP-dependent protein kinase (PKA) affects the levels of VEGF induced by nicotine treatment and how this might be modulated by HA–CD44 and p53 status, remains unclear in NSCLC. The gene discussed is TP53; the disease is non-small cell lung carcinoma.